Fate Therapeutics develops off-the-shelf cell immunotherapies made from stem cells, mainly for autoimmune diseases and cancer. It last closed at $1.02 on Nov 17, down 10.53% on the day.
Only 1 firm rated FATE in the past 90 days, not enough for a consensus
Average 12-month target
$3.00
▲ 194.1% upside
Based on 1 analyst who set a price target on FATE in the past 90 days. The average target is $3.00, with a high of $3.00 and a low of $3.00, compared with the last close of $1.02.
Low $3.00Avg $3.00High $3.00
Blue marker: last close $1.02
Highest target$3.00
Average target$3.00
Lowest target$3.00
Latest rating changes
Wells FargoTarget lowered
Nov 6Hold$3.50 → $3
Piper SandlerReiterated
Aug 14Buy$8
Wells FargoMaintained
Aug 14Hold$3.50
WedbushReiterated
Aug 14Buy$7
HC Wainwright & Co.Reiterated
Jun 8Buy$7
Date
Firm
Action
Rating
Price target
Nov 6
Wells Fargo
Target lowered
Hold
$3.50 → $3
Aug 14
Piper Sandler
Reiterated
Buy
$8
Aug 14
Wells Fargo
Maintained
Hold
$3.50
Aug 14
Wedbush
Reiterated
Buy
$7
Jun 8
HC Wainwright & Co.
Reiterated
Buy
$7
Loading…
Technical Analysis
FATE · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 80% below its 20 day and 106% below its 50 day average. It is 95% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 19), oversold. The nearest support is the Pivot S1 at $0.98, and the nearest resistance the Pivot at $1.05.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 16.0%/day
Key levels
$3.2352 week high+216.7%
$2.37100 day average+132.4%
$2.15Swing high (Oct 20)+110.8%
$2.1050 day average+105.9%
$1.99200 day average+95.1%
$1.8420 day average+80.4%
$1.10Pivot R1+7.8%
$1.05Pivot+2.9%
$1.02Last close
$0.98Pivot S1−3.9%
$0.9552 week low−6.9%
Indicators
RSI (14)
19.20
Oversold below 30
Oversold
MACD
-0.25
Below its signal line
Bearish
Stochastic
3.2
Near the bottom of its range
Oversold
ADX (14)
25.6
Trending down
Williams %R
-99.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-194.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−50.0%
Change over 10 sessions
Bearish
ATR (14)
$0.16
Typical daily range, 16.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 39.8%/day
Key levels
$3.2352 week high+216.7%
$2.37100 day average+132.4%
$2.15Swing high (Oct 20)+110.8%
$2.1050 day average+105.9%
$1.99200 day average+95.1%
$1.8420 day average+80.4%
$1.10Pivot R1+7.8%
$1.05Pivot+2.9%
$1.02Last close
$0.98Pivot S1−3.9%
$0.9552 week low−6.9%
Indicators
RSI (14)
34.40
Weak, oversold below 30
Neutral
MACD
-0.13
Below its signal line
Bearish
Stochastic
4.0
Near the bottom of its range
Oversold
ADX (14)
27.9
Trending down
Williams %R
-99.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-243.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−55.8%
Change over 10 sessions
Bearish
ATR (14)
$0.41
Typical daily range, 39.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for FATE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how FATE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow FATE usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How FATE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FATE is in one of them and how their past FATE trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops off-the-shelf cellular immunotherapies, mainly CAR T-cell and natural killer cell product candidates made from induced pluripotent stem cells. Its current focus is on treating autoimmune diseases such as lupus, along with cancer, and its candidates are being studied in clinical trials for patients with these conditions.